EarningsQ2 2026 Earnings Report
MX:INDV1 Q2 2026 EPS Results
Actual EPS$19.59
Consensus EPS$14.80
Beat/MissBeat by +$4.79
One Year Ago EPS$8.69
MX:INDV1 Q2 2026 Revenue Results
Actual Revenue$5.84B
Expected Revenue$5.22B
Beat/MissBeat by +$626.30M
YoY Revenue Growth+13.58%
Earnings Announcement Details
QuarterQ2 2026
Date08/03/2026
TimeBefore Open
Conference CallMonday, August 3, 2026
MX:INDV1 Upcoming Earnings
Indivior's next earnings date is estimated for October 29, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
MX:INDV1 Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
Overall the call presents a constructive and optimistic view of the merger: management emphasized scale, a diversified portfolio (~$2.2B pro forma revenue), strong pro forma profitability (adjusted EBITDA $888M; ~41% margin), and $125M of near-term cost synergies, while retaining balance sheet strength and highlighting SUBLOCADE as a durable, large growth driver (~44% of revenue) supported by IP and commercial momentum. Noted risks include revenue concentration in SUBLOCADE, increased pro forma net debt (~$878M, ~1x leverage), absence of quantified revenue synergies, and standard integration and regulatory execution risks. On balance, the positives (scale, margins, synergies, product durability) outweigh the lowlights.Company Guidance
Pro Forma Scale and Revenue
Combined company pro forma net revenue of approximately $2.2 billion (trailing 12 months ended June 30, 2026), creating a scaled CNS leader across addiction, ADHD, depression, and Parkinson's disease.
Strong Pro Forma Profitability
Pro forma adjusted EBITDA of $888 million with an adjusted EBITDA margin of ~41%, up from Supernus margin ~18% and reflecting combined operating leverage and anticipated synergies.
Material Cost Synergies
Expected annual cost synergies of $125 million, primarily from G&A and operational efficiencies, anticipated to be realized within the first 12 months post-close.
SUBLOCADE as a Durable Growth Driver
SUBLOCADE expected to be the largest single contributor (~44% of pro forma net revenue); recorded quarter had record new patient starts and stable market share (~76% for ~6-7 quarters).
Diversified Commercial Portfolio and Growth Products
Combined commercial portfolio of 11 marketed medicines with five named growth products (SUBLOCADE, Qelbree, ZURZUVAE, Gocovri, Onapgo) anticipated to drive growth well into the 2030s.
Balance Sheet and Structural Deal Terms
All-stock, tax-free merger of equals with exchange ratio of 1.5401 Indivior shares per Supernus share; pre-closing Indivior dividend of $1.0 billion to Indivior stockholders; post-close ownership ~56.5% Indivior / ~43.5% Supernus (fully diluted).
IP and Product Durability for SUBLOCADE
SUBLOCADE supported by 12 Orange Book-listed patents spanning 2031–2038, with additional patent applications under pursuit that could extend protection toward 2042–2044; manufacturing complexity cited as a barrier to generic entrants (no Paragraph IV challenges to date).
Cash / Debt Position Before and After Combination
Supernus cash of ~$372 million and no debt as of June 30, 2026; Indivior net debt $251 million (net leverage ~0.4x) leading to combined net debt of ~$878 million and pro forma net leverage of ~1x.
Execution Track Records and Completed Initiatives
Indivior reports completion of its Action Agenda phases (growth of SUBLOCADE, simplification, stronger financial position); Supernus has recent M&A experience (Sage acquisition) and new product launches (Onapgo), supporting integration credibility.
MX:INDV1 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed